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 Abstract 
 Background: This study assessed the quality of life (QoL) and 
the implication of time effort of everolimus treatment in pa-
tients with metastatic renal cell carcinoma (mRCC).  Meth-
ods: Adult patients with mRCC were eligible for everolimus 
treatment after first-line vascular endothelial growth factor 
receptor (VEGFR) tyrosine kinase inhibitors or bevacizumab 
therapy. The primary end-point, QoL, was assessed by means 
of the NCCN-FACT FKSI-19 questionnaire.  Results: In total, 
202 patients (24% of female patients; median age, 71 years) 
were evaluable for QoL analyses. The median treatment du-
ration was 4.4 months (95% CI, 3.8–5.3) and the median time 
to progression was 6 months (95% CI, 5.4–7.5). The median 
FKSI-19 total score remained stable during treatment (52.0 
at therapy start, 55.0 at observation end). The median time 
effort spent on total therapy was 20 hours per patient. Most 
of the patients stated to have “no limitations,” “a little” or 
“moderate” limitations in their daily, social, and professional 
lives. Two months after the start of treatment, 65 patients 
reported none or a little time burden due to therapy.  Conclu-
sions: QoL was maintained during the everolimus therapy 
and limitations as well as time effort were acceptable for 
most of the patients. The study supports previous findings 
on switching mode of action after anti-VEGFR–targeted ther-
apy to a mammalian target of rapamycin inhibitor. 
 © 2019 S. Karger AG, Basel 
 Introduction 
 The approval of targeted drugs has been a milestone in 
the therapy of metastatic renal cell carcinoma (mRCC). 
Vascular endothelial growth factor receptor tyrosine ki-
nase inhibitors (VEGFR-TKIs) have shown clinical ben-
efit for patients with treatment naïve or cytokine-pre-
treated RCC by extending progression-free survival (PFS) 
or overall survival (OS)  [1, 2] . Further increase in the pro-
longation of median OS is possible the with sequential 
treatment of targeted drugs after the first-line therapy 
with VEGFR-TKIs  [3] . Activation of the mammalian tar-
get of rapamycin (mTOR) pathway as a potential resis-
tance principle of tyrosine kinases provides a rationale for 
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the change in therapeutic strategy after the treatment 
with a first-line VEGFR-TKI in patients with mRCC.
 Everolimus, inhibitor of mTOR, was the first drug to 
show efficacy after the failure of a targeted therapy in pa-
tients with mRCC with a prolonged PFS (4.9 months vs. 
1.9 months, hazard ratio (HR), 0.33;  p < 0.001) in a con-
trolled clinical trial, RECORD-1 (Renal Cell cancer treat-
ment with Oral RAD001 given Daily)  [4] . The median OS 
was 14.8 months in the RECORD-1 study, but was not 
significantly longer compared to the placebo probably 
due to crossover from placebo to the everolimus arm ( p = 
0.18)  [4] . However, the survival corrected for crossover 
was 1.9-fold longer (95% confidence interval (CI), 0.5–
8.5) with everolimus compared to placebo only  [4] . Later, 
RECORD-3 study demonstrated a strong trend support-
ing standard treatment paradigm of sunitinib-everolimus 
sequence, with a median OS of 32.0 months.
 Everolimus (Afinitor ® ) is approved for the treatment 
of patients with mRCC after the failure of VEGF-targeted 
therapy in the European Union and in the United State of 
America  [5–7] . At the time of this study start, second-line 
treatment with everolimus after the failure of VEGF-tar-
geted therapy was a standard treatment option as recom-
mended by international guidelines  [8, 9] . The approval 
of new TKIs and immunotherapeutic agents for the sec-
ond-line treatment of mRCC, since the start of the study, 
limits everolimus use in the second-line treatment; how-
ever, everolimus is still a valid treatment option in this 
setting  [9–11] .
 The improvement in survival based on continuous 
treatment requires in-depth analysis of patient’s quality 
of life (QoL) in order to assess the risk-benefit ratio, espe-
cially in the second-line treatment  [12] . Therefore, Cella 
and coworkers recommended measuring QoL in the sec-
ond-line treatment of mRCC  [13] .
 To gain more insight into QoL of the patients during 
the second-line treatment with everolimus under routine 
conditions, this study aimed to assess the following: (a) 
QoL using patient-reported outcome (PRO) question-
naires; (b) time burden due to medical visits/activities; (c) 
QoL based on time burden; (d) analysis of treatment se-
quences; (d) adverse events (AEs) during routine care 
with everolimus; and (e) time from baseline to progres-
sion.
 Patients and Methods 
 Study Design 
 EVERPRO (evaluation of quality of life in second-line treat-
ment with everolimus in patients with metastatic renal cell carci-
noma) was a prospective, single-arm, non-interventional study of 
second-line everolimus administered per routine clinical practice 
in patients with mRCC from registered sites in Germany. This 
non-interventional study was performed as a multicenter study in 
75 oncological centers.
 Patients and Treatment 
 Adult patients (aged  ≥ 18 years) with mRCC, who had previ-
ously received no more than 1 drug for the treatment of RCC fol-
lowed by the physician’s decision to treat with everolimus, were 
included in the study. Patients were ineligible if they were partici-
pating in an interventional clinical trial at the same time. The 
planned enrollment was 350 patients in up to 150 centers; due to 
slow patient accrual, the study was terminated after 209 patients 
(in 75 active centers).
 Everolimus was used according to the approved product label 
in Europe. Patients received everolimus 10 mg once daily orally 
until disease progression or unacceptable toxicity occurred. The 
dose interruptions and/or reductions to 5 mg/day were allowed to 
manage side effects.
 Analysis populations were defined as total population (all eli-
gible patients documented at baseline) and analysis population (all 
patients of the total population with documented evidence of 
everolimus intake and at least 1 documented information under 
treatment). To get conclusive results, the observation period of this 
study was equivalent to the treatment duration with everolimus; 
hence, the study ended 12 months after the inclusion of the last 
patient in this study. Patient observation period started in July 
2012 and ended in September 2016. Patient records, the patient 
registration form, and questionnaires for assessment of QoL were 
used as data sources. All data including AEs were documented in 
the electronic case report form (eCRF). 
 Assessment of HRQOL 
 The primary objective of the study was to assess the health-re-
lated QoL (HRQOL). HRQOL was assessed using National Com-
prehensive Cancer Network/Functional Assessment of Cancer 
Therapy-Kidney Symptom Index 19 (NCCN-FACT FKSI-19) 
questionnaire and distance- and treatment time (DTT) question-
naire. NCCN-FACT FKSI-19 covered 4 subscales of the FKSI 
(DRS-P, disease-related symptoms subscale–physical; DRS-E, dis-
ease-related symptoms subscale–emotional; TSE, treatment side 
effects subscale; FWB, function and well-being subscale)  [12] . The 
higher the subscores or the total score, the better is the QoL. The 
subscales were evaluable, if at least 50% of respective items were 
answered. The FKSI-19 questionnaire as a whole (= total score) 
was evaluable, if all subscales were evaluable and at least 80% of all 
items were answered. Valid observations were patients who filled 
out the questionnaires in such a way that questionnaires were eval-
uable with regard to the respective subscale or total score. Based 
on a report by Rao and colleagues  [12]  that takes into account 
minimally important differences (MIDs), a change plus or minus 
6 points was considered
 MID (minimally clinically relevant change) + (improvement) 
 MID (deterioration)
 scored.
 DTT questionnaire included the collection of data related to 
the time burden for visits at the treating physician or at the hospi-
tal (ambulatory or in-house), home visits, services of caretakers, 
phone contacts, and further measures. The time required includes 
the total time spent for visits at the physician’s place, visits at home, 
other contacts to physician, hospital visits, stays in rehabilitation 
clinics, and further therapeutic measures. The documentation of 
findings and patient questionnaires was collected at the study in-
clusion, and after 1, 2, 4, 6, 8, 10, and 12 months and so on, and at 
the treatment end. The distance- and time questionnaire was 
skipped at the inclusion into the study and at the documentation 
time point after 1 month. The FKSI-19 was skipped at 1 month 
after the inclusion.
 The secondary objectives of the study included the analysis of 
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ration of treatment with everolimus, time to progression (TTP), 
PFS (time from baseline to progression or death), and safety profile 
of everolimus.
 Data Sources and Statistical Analysis 
 Physicians collected patient information in the eCRF. iOMED-
ICO provided the required software, iostudy office edc, developed 
for recording of data and adapted to study needs. This software was 
password protected, validated, and certified according to ISO 
9000: 2001. An audit trail was available. All the findings recorded 
in the eCRF were transferred online into the study database at iO-
MEDICO AG. Transfer of data from the questionnaire into the 
database was tested and validated before study start. The param-
eters recorded in the eCRF were demographics, Karnofsky perfor-
mance index (KPI), anamnesis of primary diagnosis (date, TNM 
classification, histological subtype, localization of tumor, Memo-
rial Sloan Kettering Cancer Center [MSKCC] score at first-line), 
anamnesis of first appearance of metastasis (date, site of metasta-
sis), number of resected and involved lymph nodes.
 The coding of AEs was performed according to the Medical 
Dictionary for Regulatory Activities version 17.0 or higher and 
graded using the Common Terminology Criteria for Adverse 
Events version 4.03  [14] . For all serious AEs (SAEs), the potential 
causal relation to everolimus was assessed and documented by the 
treating physician. In the case that no information regarding po-
tential relation was provided, a causal relationship to everolimus 
was assumed. All AEs were documented starting with the first ad-
ministration of everolimus (independent of causality) until 30 days 
after the end of treatment.
 The statistical analyses were performed using statistical version 
10 (StatSoft Europe GmbH), SAS version 9.4, and statistics pro-
gramme R, version 2.15.1 (www.r-project.org) and was based on 
the guidelines of the Committee for Proprietary Medicinal Prod-
ucts, “Biostatistical Methodology in Clinical Trials,” and the ICH 
guidance E9 “Statistical Principles for Clinical Trials”.
 Results 
 Patient Demographics 
 A total of 209 patients from 75 sites were included in 
the study; for whom, the inclusion visit was documented. 
The safety population as well as the efficacy population 
 Table 1.  Baseline characteristics of analysis population (n = 202)
Characteristics n = 202
Age, median years (range) 71 (23–88)
Male, n (%) 153 (76)
KFI at study entry (n = 121),
median index (range) 80 (50–100)
Localization of tumor, n (%)
Left 112 (55.4)
Right 89 (44.1)
Both sides 1 (0.5)
Clear cell histology, n (%) 164 (81.2)





Tumor stage (TNM at initial diagnosis), n (%)
I (T1, N0, M0) 20 (10)
II (T2, N0, M0) 16 (8)
III (T2, T3, N0, N1, M0)a 31 (15)
IV 83 (41)





Synchrone metastases, n (%) 71 (35)
Metachrone metastases, n (%) 131 (65)
Patients with prior nephrectomy, n (%) 185 (92)





 KFI = Karnofsky performance index, MSKCC = Memorial 
Sloan Kettering Cancer Center, TNM = classification of malignant 
tumors.
a Classification according to the European Association of Urol-










 Fullfilled inclusion criteria
 Received everolimus
 Further information available  
during therapy (n = 202)  
2 patients without medication
2 patients without further information 
during therapya
3 patients received temsirolimus in
 first-line
a For both patients, the inclusion documentation was available, but observation end was documented in 1 patient only.     b Final documentation was completed.
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 Fig. 2. Therapy sequences for analysis population (n = 202). BEV = bevacizumab, IFNα = interferon alpha. 
 Fig. 3. PFS in analysis population (n = 202). 
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involves 202 patients (analysis population); for whom, at 
least 1 prescription of everolimus was documented and at 
least 1 further information under therapy was available 
( fig. 1 ).
 The median observation time (the first prescription of 
everolimus until the last contact or death) was 6.41 months 
(95% CI, 5.69–8.05). The number of patients declined to 
164 at 2 months after the inclusion visit. At month 10 pa-
tient number decreased to 41 patients, at month 16 to 20 
patients, at month 20 to 12 patients and after month 24, 
the number dropped to <10 patients. The baseline char-
acteristics of the analysis population are shown in  table 1 .
 Therapy Sequences 
 Of the 202 patients, 171 (84.7%) completed the therapy 
with everolimus by the end of their individual observation 
period of 12 months. Further therapy was planned for 103 
patients, and the planned therapy sequences post everoli-
mus treatment for these patients are shown in  figure 2 .
 Exposure 
 The median duration of everolimus treatment for the 
analysis population was 4.4  months (95% CI, 3.8–5.3). 
The median absolute dose intensity for patients with a 
documented date therapy end (n = 189) was 62.6  mg/
week (range, 5.5–70 weeks), and the median relative dose 
intensity was 89.4% (range, 7.9–100%).
 Efficacy 
 The median TTP for the analysis population was 6.0 
months (95% CI, 5.4–7.5). After stratifying the patients 
based on the duration of first-line therapy, the median 
TTP did not differ markedly between the groups. The me-
dian PFS was 5.7 months (95% CI, 4.8–7.1) ( fig. 3 ); the 
PFS results of subgroup analyses based on MSKCC risk, 
histology, response to first-line treatment, and the dura-
tion of first-line treatment were not conclusive. The sum-
mary of events is shown in  table 2 .
 Safety 
 Overall, 167 patients (82.7%) experienced 804 AEs in 
total including 314 SAEs. The most commonly reported 
AEs were malignant neoplasm progression (17%), dys-
pnea (16%), fatigue (14%), and anemia (14%) ( table 3 ). 69 
patients (34.2%) discontinued due to an AE, of these, 29 
(14%) were considered to be related to everolimus. Of the 
total AEs, 347 were known to be treatment related includ-
ing 287 grade 1 or 2 and 49 grade 3 or 4 AEs, respectively. 
A total of 118 patients (58.4%) experienced 314 SAEs, of 
 Table 3.  Adverse events occurring in ≥4% of patients in the analsis 
population (n = 202)
All grades
(n = 202)
Grade 3 or 4
(n = 202)
n (%) n (%)
Patients with adverse event (any event) 167 (83) 71 (35)
Malignant neoplasm progression 34 (17) 5 (3)
Dyspnea 33 (16) 6 (3)
Fatigue 29 (14) 3 (1)
Anemia 28 (14) 10 (5)
Diarrhea 20 (10) 2 (1)
Edema peripheral 19 (9) 1 (<1)
Nausea 19 (9) 2 (1)
Cough 18 (9) 0
Stomatitis 18 (9) 2 (1)
Rash 16 (8) 0
Decreased appetite 15 (7) 0
General physical health deterioration 14 (7) 4 (2)
Back pain 14 (7) 6 (3)
Epistaxis 13 (6) 0
Pleural effusion 13 (6) 4 (2)
Weight decreased 12 (6) 2 (1)
Pain 11 (5) 3 (1)
Pyrexia 11 (5) 0
Pneumonitis 11 (5) 1 (<1)
Mucosal inflammation 8 (4) 1 (<1)
Vomiting 8 (4) 0
Pruritus 8 (4) 0
Hyperglycemia 8 (4) 6 (3)
 Table 2.  Summary of events in analysis population (n = 202)
Duration of therapy TTP PFS
Censoring if no documentation of end of 
therapy or death in eCRF
if no documentation of 
progression
if no documentation of 
progression or death
Time of censoring last known intake of everolimus date of last contact date of last contact
Total patients 202 202 202
Censored, n (%) 30 (14.9) 80 (39.6) 55 (27.2)
Not censored, n (%) 172 (85.1) 122 (60.4) 147 (72.8)
Duration
Median (95% CI), months 4.4 (3.8–5.3) 6 (5.4-7.5) 5.7 (4.8–7.1)
Upper quartile 2.3 (1.9–2.7) 3.6 (3–4.3) 3.4 (2.5–3.9)
Lower quartile 8.7 (7.1–11.6) 15.2 (10.7–23.2) 12.2 (8.8–15.4)
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which, 100 SAEs (12.4% of 804 AEs) in 58 patients were 
assessed as being related to treatment with everolimus. 42 
patients (20.8%) died during the study including 7 deaths, 
which were assessed to be related to everolimus.
 Patient-Reported Outcomes 
 Evaluation of QoL 
 A total of 692 of 1021 questionnaires provided to pa-
tients (67.8 ± 9.4%) were filled and returned to the physi-
cians. The mean proportion of missing items in the whole 
questionnaire was 4.7% and was higher in the DTT ques-
tionnaire compared to the FKSI-19 (8.4% ± 12.6% vs. 
1.7% ± 6.5%). The median FKSI-19 total score remained 
stable during the treatment (52.0 at therapy start, 55.0 at 
observation end) ( fig. 4 ).
 FKSI-19 subscales were DRS-P, DRS-E, TSE, FWB. 
The median score for DRS-P was 36.0 at baseline and 
37.5 at the end of observation with a maximum score of 
48. The maximum median improvement as compared to 
baseline was 3.4 points at month 16 and the maximum 
median change for the worse was -3 points at month 4, 
6, 8 and 28. The median score for DRS-E was 2.0 at base-
line and 1.0 at the end of observation with a maximum 
score of 4. There were only small changes in scores 
throughout the study, mainly after month 16. No change 
for the worse was reported during the course of the study, 
the maximum median improvement was 4.0 points at 
month 40.
 Median scores for TSE were 10.0–12.0 throughout the 
observation period, with a median score of 9.0 at the end 
of observation with a maximum score of 12. There were 
no changes for the worse during the observation time and 
the maximum median improvement was 2.5 points at 
month 18. Median scores for FWB were between 5.0–10.5 
throughout the observation period with a median score 
of 6.0 at the end of the observation period and a maxi-
mum score of 12. As compared to the median score at the 
inclusion visit, the maximum median improvement was 
3.0 points at month 18, 22, 36 and thereafter. The maxi-
mum median decrease was –3.0 points recorded at month 
34. 
 Altogether, the median change in total score increased 
slightly until month 24 with a maximum improvement of 
8.4 points at month 16 as compared to the inclusion visit. 
The median change in total FKSI-19 score, overall/obec-
tive response rate (ORR) and disease control rate (DCR) 
by month is shown in  figure 5 .
 Questionnaire of Time Burden Due to Medical 
Visits/Activities and Expenditure of Time Measured 
in Hours 
 During the entire study duration, a median of 20.0 h 
was spent for therapy by each patient (0.0–2465.0 h; n = 
191 observations, data of 11 patients missing) ( fig. 6 a). In 
total, 72.3% of the patients reported that they had visited 
a physician at least once; 3.0% of patients reported no 
physician visits, and no information was available for 
24.8% of patients ( fig. 6 b). The median number of physi-
cian visits was 11.0 visits per patient throughout the ob-
servation time (range, 0.0–108.0 visits; n = 142); the total 
median time spent for visiting the physician was 18.0 h 
(0.0–136.0 h; n = 140).
 Limitations in Daily Activities 
 Most of the patients stated to have “no limitations,” “a 
little,” or “moderate limitations” in their daily, social, and 
professional lives.
 At the first observation point (month 2), data regard-
ing limitations in daily routine were available for 122 of 
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 Fig. 6.  A Total time effort needed for therapies in analysis population (n = 191). The data of 11 patients are missing.  B Physician consul-
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that they were not limited at all, 37 patients (22.6%) as-
sessed their limitation as “a little,” 35 patients (21.3%) 
stated that they were “moderately limited,” and 22 pa-
tients (13.4%) stated that they were “considerably limit-
ed.” 8 patients (4.9%) assessed their limitations as “se-
vere.” No information was available from 42 patients 
(25.6%) ( fig. 7 a).
 Limitations in daily routine decreased slightly until 
month 10; at the bimonthly observation points, 15.3% at 
month 4 (n = 124), 16.7% at month 6 (n = 84), 16.9% at 
month 8 (n = 59), and 17.1% at month 10 (n = 41) stated 
that they had no limitations and 16.9, 22.6, 25.4, and 
26.8% stated that they were only “a little” limited. In ad-
dition, there were only 4.8, 3.6, 3.4, and 0.0% of patients 
that were severely limited at these time points. However, 
the number of evaluable patients decreased from 124 pa-
tients at month 4 to 41 patients at month 10, and for 
those, there were 25% to 30% of data missing. For 191 
patients, the observation end was documented; of which, 
3.7% assessed their limitations as not limited, 5.8% “a 
little” limited, 2.1% as moderate, 3.7% considerably lim-
ited, and 1.6% considered their limitations “severe” 
( fig. 7 a).
 Total scores were calculated based on the 4 subscores 
related to limitations, including limitations in the daily 
routine, limitations in activity, limitations in professional 
life, and limitation caused by time burden. The total 
scores decreased during the observation period; however, 
the number of observations is very low ( fig. 7 b).
 Discussion 
 Over the past decade, there has been a significant ad-
vancement in the treatment of mRCC, with the approval 
of targeting agents inhibiting VEGF and mTORC1. Vari-
ous studies including the randomized phase 2 RECORD-3 
study  [6] and the real-world non-interventional CHANGE 
study  [5] demonstrated the benefit of switching mode of 
action from VEGFR to mTOR. However, HRQOL out-
comes have not been sufficiently documented in patients 
who receive second-line everolimus. This study provides 
a comprehensive overview of HRQOL that patients with 
mRCC experience during the second-line treatment with 
everolimus.
 The patient population included in this study is at least 
representative of patients with mRCC in Germany, as pa-
tients were included based on the European Medicines 
Agency approval status and the study sites were distrib-
uted equally. With the broad inclusion criteria, patient 
characteristics of the study population are in accordance 
with the general mRCC patient population allowing the 
results to be generalizable and relevant to the larger pop-
ulation. Therapy sequences observed during this study 
mirror the treatment landscape of mRCC in Germany be-
fore the approval of nivolumab, cabozantinib, and lenva-
tinib. Sunitinib and pazopanib appeared to be the stan-
dard treatment options in the first-line setting while bev-
acizumab in combination with interferon-α and sorafenib 
played a subordinate role.
 The duration of everolimus exposure may have the im-
pact-associated symptoms as well as HRQOL in individ-
ual patients. Patients in this study had longer everolimus 
treatment duration with 4.4 months (95% CI, 3.8–5.3) 
compared to the RECORD-1 trial  [15] .
 The results of the current study support the use of 
everolimus as post VEGFR-TKI treatment option for 
mRCC under “real-world conditions” with comparable 
efficacy as noted in the clinical trials in terms of median 
PFS ( ∼ 5.7 months) and TTP ( ∼ 6.0 months). Regardless 
of the drug administered, the second-line PFS was com-
paratively shorter in a German RCC registry (4.3 months) 
 [16] . Similarly, PFS was longer in this study compared to 
RECORD-1 (4.9 months)  [15] and a little shorter than the 
PFS of the CHANGE study (6.9 months)  [5] . Due to the 
non-interventional nature of the study, no predefined tu-
mor evaluation was performed, and the data are missing 
for a relatively high proportion of patients, which may 
lead to a bias in the efficacy results.
 MSKCC risk, histology, response to first-line treat-
ment, and duration of first-line treatment were used as 
stratification factors for subgroup analyses. However, the 
results of these analyses are not conclusive. Analysis of 
the median time to increase or decrease in Karnofsky per-
formance status (KPS) data was not sufficient to draw any 
conclusions, since most of the patients were censored 
very early due to missing KPI assessments.
 The safety profile of everolimus was consistent with 
the results of prior trials and German SmPC  [7] . Overall, 
most AEs were manageable and the risk-benefit ratio was 
acceptable in the context of clinical benefit in patients 
with a fatal disease. Commonly reported AEs that were 
related to everolimus were stomatitis, dyspnea, fatigue, 
rash, nausea, and anemia. The majority of everolimus-
related SAEs were respiratory, thoracic, and mediastinal 
disorders that occurred in  ∼ 10% of patients. Drug-related 
pneumonitis, a known class effect toxicity of rapalogs, 
was reported in 5.4% of patients. Thus, heightened aware-
ness on this toxicity, appropriate diagnosis and manage-
ment are crucial to optimize patient safety. The lack of 
prespecified toxicity management guidelines may have 
contributed to a high percentage (34.2%) of treatment 
discontinuation due to AEs in this non-interventional 
study than RECORD-1 study (10%)  [15] .
 Similar to the previous reports  [4, 15, 17] , treatment 
with everolimus seems to improve the QoL although this 
effect appears marginal; however, everolimus certainly 
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mained stable or showed marginal increase without any 
significant change even after 10 months of observation. A 
review on the available HRQOL data from clinical trials 
noted that everolimus significantly delays and reduces the 
degree of KPS deterioration regardless of the tumor size 
 [18] .
 Questionnaires and PRO instruments used in the 
study covered all relevant domains of RCC. The DTT 
questionnaire was developed and used for the first time 
in this study while NCCN-FACT FKSI-19 questionnaire 
is a validated and widespread tool to investigate QoL of 
patients with RCC. Overall, about 70% of the question-
naires were returned, and the median FKSI-19 scores and 
also the FKSI subscores were stable till month 8; then, the 
trend showed an improvement in scores. Since the num-
ber of questionnaires decreased rapidly, especially after 
month 8, only few observations were available, which 
made the interpretations difficult. Therefore, it might be 
the case that the questionnaires collected after 10 months 
were completed mostly by patients who were long-term 
responders with a well-tolerated safety profile.
 Higher scores for PROs indicated an improved well-
being, which was influenced by factors related to the AE 
profile and effectiveness of everolimus. An important as-
sociation exists in the correlation of tumor response and 
measures of change in PROs  [19] . It was demonstrated 
that PRO response duration was shorter than tumor re-
sponse duration suggesting that the patients might detect 
worsening conditions before oncologists can detect can-
cer progression  [19] . Overall, patients with higher QoL at 
baseline with a FKSI-19 total score of  ≥ 52 did better 
throughout the study. Herrmann et al.  [20] previously 
noted that the global HRQOL at baseline was significant-
ly associated with tumor response, and patients with high 
baseline scores achieved significantly longer median PFS 
than those with baseline scores less than or equal to the 
median score.
 Limitations questionnaire analyzed the data round key 
4 limitations including “limitations in daily routine,” “so-
cial activities” and “professional life,” and “time burden 
due to therapy.” Majority of the patients assessed their 
limitations as “no limitations,” “very little,” or “moder-
ate” throughout the observation period.
 Non-interventional nature of this study was the pri-
mary limitation to detect the true association of PROs. 
Since no predefined schedule and broad inclusion criteria 
were preset, the internal validity of the data collected is 
limited. The study did not require standardized tumor 
response evaluation; hence, the tumor evaluations were 
not uniform and were performed at the discretion of the 
local investigator. In order to ensure an adequate docu-
mentation quality, a sample monitoring was performed 
during this non-interventional study, thus leading to the 
high documentation quality.
 In conclusion, this non-interventional EVERPRO 
study reflects routine use of second-line everolimus in pa-
tients with mRCC. The present authors demonstrate that 
the QoL is maintained during everolimus therapy, and 
the treatment-associated limitations as well as the time 
efforts are acceptable for most patients. The study sup-
ports previous findings on switching mode of action after 
anti-VEGFR–targeted therapy to an mTOR inhibitor. 
Treatment duration, efficacy and safety results are consis-
tent with the second-line data for everolimus after VEG-
RF-TKIs from prior studies and German SmPC.
 Online Supplemental Material 
 Online Supplemental Fig. 1. Map of represented study centers 
in Germany.
 To access the online supplemental figure, please refer to  www.
karger.com/?DOI=494278 .
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